Spiegel and colleagues carried out a phase I clinical study on dual-targeting CD19/CD22 CAR T-cells in patients with relapsed/refractory B-ALL and LBCL (NCT03233854). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.